Publications

@article{Jayaraman2021-gq,

title = {Targeting protein kinase CK2 in the treatment of 

 cholangiocarcinoma},

author = {Padma-Sheela Jayaraman and Kevin Gaston},

year  = {2021},

date = {2021-10-01},

journal = {Explor. Target. Antitumor Ther.},

volume = {2},

number = {5},

pages = {434\textendash447},

publisher = {Open Exploration Publishing},

abstract = {Cholangiocarcinoma (CCA) is a disease with a very poor prognosis 

 and limited treatment options. Although targeted therapies 

 directed towards specific mutations found in CCA are becoming 

 available and are showing great potential, many tumors do not 

 carry actionable mutations and, in those that do, the emergence 

 of drug resistance is a likely consequence of treatment. 

 Therapeutic targeting of enzymes and other proteins that show 

 elevated activity in CCA cells but which are not altered by 

 mutation is a potential strategy for the treatment of target 

 negative and drug-resistant disease. Protein kinase CK2 (CK2) is 

 a ubiquitously expressed kinase that has increased expression 

 and increased activity in a variety of cancer types including 

 CCA. Several potent CK2 inhibitors are in pre-clinical 

 development or under assessment in a variety of clinical trials 

 often in combination with drugs that induce DNA damage. This 

 review outlines the importance of CK2 in CCA and assesses the 

 progress that has been made in the evaluation of CK2 inhibition 

 as a treatment strategy in this disease. Targeting CK2 based on 

 the expression levels or activity of this protein and/or in 

 combination with drugs that induce DNA damage or inhibit cell 

 cycle progression, could be a viable option for tumors that lack 

 actionable mutations, or for tumors that develop resistance to 

 targeted treatments.},

keywords = {apoptosis, casein   kinase II, Cholangiocarcinoma, DNA damage response, dose-dependent synthetic lethality, methuosis, protein kinase CK2},

pubstate = {published},

tppubtype = {article}

}